TICKERNERD
Menu
GEHCGEHCHealthcare · Medical Devices

GEHC Stock Forecast: GE Healthcare Technologies, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$74
−0.14% on the day

The 19 Wall Street analysts covering GE Healthcare Technologies, Inc. hold a median 12-month price target of $83 — +12.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 13 Aug 2026 — in the upper half.

Market cap
$32.6B
Ticker Nerd rank
64 / 100
Median analyst target
$83
Analysts covering
19
Total return, dividends reinvested
1W
+2.7%
1M
+19.6%
YTD
−10.0%
1Y
+0.2%
From 52W high
−16.3%
From 52W low
+23.9%
$59
$88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GEHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GE Healthcare Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Volatility
87
Issuance
84
Revisions
62
Quality
58
Growth
50
Momentum
44
Accruals
37
Size
7

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GEHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GEHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100Oct 25Jan 26Apr 26Jul 26GEHCHigh $96Median $83Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says19 analysts
14 Buy5 Hold0 Sell
Low $70Median $83High $96

The green dot is the last close — the median target sits +12.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
31 July 2026UBSMaintainsNeutral$67 → $73
30 July 2026CitigroupMaintainsNeutral$69 → $75
30 July 2026Evercore ISI GroupMaintainsOutperform$80 → $84
30 July 2026Wells FargoMaintainsOverweight$75 → $85
29 July 2026BTIGMaintainsBuy$75 → $79
17 July 2026Hovde GroupInitiatesMarket Perform—
16 July 2026UBSMaintainsNeutral—
16 July 2026UBSMaintainsNeutral$69 → $67
9 July 2026BMO CapitalInitiatesMarket Perform—
23 June 2026RBC CapitalInitiatesOutperform—
21 May 2026UBSUpgradeNeutral—
30 Apr 2026BarclaysMaintainsEqual-Weight—
30 Apr 2026CitigroupMaintainsNeutral—
30 Apr 2026Evercore ISI GroupMaintainsOutperform—
30 Apr 2026Goldman SachsDowngradeNeutral—
30 Apr 2026JP MorganMaintainsNeutral—
30 Apr 2026Wells FargoMaintainsOverweight—
29 Apr 2026BTIGMaintainsBuy—
21 Apr 2026BTIGReiteratesBuy—
17 Apr 2026Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GEHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GEHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.9%
Analysts raising
1
Analysts cutting
4
Fundamentals

GE Healthcare Technologies, Inc. (GEHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.7×

Cheaper than 45% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
3.0×

Cheaper than 35% of US stocks

EV / EBITDA
11.6×

Cheaper than 34% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 41% of US stocks

Earnings growth (YoY)
15.4%

Higher than 54% of US stocks

Gross margin
41.2%

Higher than 52% of US stocks

Operating margin
15.0%

Higher than 72% of US stocks

Net margin
9.3%

Higher than 69% of US stocks

Returns & dividend
Return on equity
19.4%

Higher than 81% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
0.2%

Higher than 3% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GEHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GEHCGE Healthcare Technologies, Inc.$32.6B
64
DXCMDexCom, Inc.$35.3B
98
STESTERIS Plc (Ireland)$23.0B
87
EWEdwards Lifesciences Corp.$53.3B
91
ZBHZimmer Biomet Holdings, Inc.$19.7B
91
BSXBoston Scientific Corp.$76.6B
57
PENPenumbra, Inc.$12.8B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GE Healthcare Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GEHC news & analysis

GEHC or LMAT: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 13 Aug 2026neutral

Zacks Investment Research published a piece comparing GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT) as potential value opportunities within the Medical Products sector. The article raises the question of which stock currently presents the better value opportunity without stating a conclusion in the provided text.

Why it matters — GEHC watchers would care because the article evaluates GEHC's value characteristics relative to a peer, offering context for how the company is viewed within its sector.

GE HealthCare (GEHC) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 12 Aug 2026positive

GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy) by Zacks Investment Research, reflecting growing optimism about the company's earnings prospects.

Why it matters — The upgrade signals increased positive sentiment from a research firm regarding GEHC's future earnings potential, which could influence broader market perception of the stock.

GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average

Zacks Investment Research · 11 Aug 2026positive

According to Zacks Investment Research, GE HealthCare Technologies (GEHC) recently crossed above its 200-day moving average, a key technical support level. The report suggests this move could indicate a long-term bullish trend from a technical perspective.

Why it matters — A GEHC watcher would care because crossing the 200-day moving average is a widely watched technical signal that may reflect a shift in the stock's longer-term trajectory.

Here's Why GE HealthCare Technologies (GEHC) is a Strong Momentum Stock

Zacks Investment Research · 7 Aug 2026positive

Zacks Investment Research highlights GE HealthCare Technologies (GEHC) as a strong momentum stock, noting that its Style Scores system helps investors identify top-rated stocks based on investing style.

Why it matters — A GEHC watcher would care because the article signals that the company is being recognized for positive momentum characteristics among stock-ranking tools.

GE HealthCare: Strong Orders, Innovation Pipeline, And PCS Recovery Point To Growth Inflection

Seeking Alpha · 6 Aug 2026positive

A Seeking Alpha analysis gives GE HealthCare a Buy rating, citing attractive risk-reward from accelerating growth, an undervalued multiple versus peers, order growth, backlog expansion, and a robust innovation pipeline. It expects Patient Care Solutions to recover as supply chain issues resolve, supporting overall growth and margin rebound.

Why it matters — The piece points to order momentum, a strong product pipeline, and a recovering Patient Care Solutions business as potential drivers of revenue acceleration and margin improvement for GEHC.

FAQ

Frequently asked questions about GEHC stock

What is the GEHC stock price forecast for 2026-2027?

The 19 Wall Street analysts covering GE Healthcare Technologies, Inc. have a median 12-month price target of $83, with estimates ranging from $70 to $96. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GEHC stock a buy right now?

Of the 19 analysts covering GE Healthcare Technologies, Inc., 14 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GE Healthcare Technologies, Inc. 64 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GEHC?

As at 13 Aug 2026, GE Healthcare Technologies, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will GEHC stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +12.6% from the last close, and Ticker Nerd's factor model ranks GE Healthcare Technologies, Inc. 64 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GEHC stock forecast for 2030?

No analyst covering GE Healthcare Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GEHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $96 over the next 12 months.

How has GEHC stock performed over the past year?

GE Healthcare Technologies, Inc. returned +0.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GE Healthcare Technologies, Inc. do?

GE HealthCare Technologies Inc. is a medical technology company that develops and manufactures imaging systems, ultrasound equipment, patient monitoring tools, and pharmaceutical diagnostics.

What is the latest news on GEHC?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "GEHC or LMAT: Which Is the Better Value Stock Right Now?". Zacks Investment Research published a piece comparing GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT) as potential value opportunities within the Medical Products sector. The article raises the question of which stock currently presents the better value opportunity without stating a conclusion in the provided text.

Company

About GE Healthcare Technologies, Inc.

GE HealthCare Technologies Inc. is a medical technology company that develops and manufactures imaging systems, ultrasound equipment, patient monitoring tools, and pharmaceutical diagnostics. The company serves hospitals, clinics, research institutions, and life sciences organizations with products and digital solutions used in diagnosis, treatment support, and workflow efficiency. Its current business is organized around four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. GE HealthCare Technologies Inc. plays a significant role in the healthcare market by supplying equipment and services that support clinical decision-making, procedural guidance, and diagnostic testing across a broad range of medical settings. Headquartered in Chicago, Illinois, the company focuses on technologies that are central to modern medical care and hospital operations.

CEO Mr. Peter J. Arduini · 54,000 employees · United States · https://www.gehealthcare.com